Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

A gene-matched Alzheimer’s drug that slows early symptoms is now approved for use. Patients will need genetic screening, fortnightly infusions, and regular brain scans to stay on treatment.

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

The drug is called Leqembi, and it removes plaques in the brain that are associated with Alzheimer's. After about 18 months, ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...